论文部分内容阅读
目的:观察艾迪注射液联合CAG方案治疗老年急性髓细胞白血病的疗效及安全性。方法:将80例患者随机分为观察组和对照组各40例。2组均采用CAG方案:阿糖胞苷(Ara-c)10 mg/m2,皮下注射q12 h(第1～14天);阿克拉霉素(Acl a)10～14 mg/(m.2d),静脉注射(第1～4天);粒系集落刺激因子(G-CSF)200μg/(m.2d),皮下注射(第1～14天)。观察组同时加用艾迪注射液50 mL/d,静脉滴注(第1～14天)。结果:完全缓解率观察组75.00%,对照组62.50%,2组差异显著(P<0.05);总有效率观察组85.00%,对照组75.00%,2组差异显著(P<0.05)。1年生存率观察组为65.00%,对照组为45.00%,2组相比差异显著(P<0.05);3年生存率观察组为37.50%,对照组为25.00%,2组相比差异显著(P<0.05)。身心健康、心理健康、社会关系、环境因素等指标治疗后观察组分别(25.7±6.2)(23.3±3.7)(23.7±6.4)(22.4±4.6)分,对照组分别为(15.7±6.2)(14.3±3.7)(14.7±6.4)(17.4±4.6)分,2组均明显好转(P<0.05),观察优于对照组(P<0.05)。结论:艾迪注射液联合CAG方案治疗老年急性髓细胞白血病疗效确切,相对安全,耐受性好。
Objective: To observe the efficacy and safety of Aidi Injection and CAG in the treatment of senile acute myeloid leukemia. Methods: 80 patients were randomly divided into observation group and control group, 40 cases each. CAG regimen was used in both groups: Ara-c 10 mg / m2, subcutaneously q12 h (days 1-14), Acla a 10-14 mg / (m.2d ), Intravenous injection (days 1 to 4), granulocyte colony stimulating factor (G-CSF) 200μg / (m.2d), subcutaneous injection (days 1-14). The observation group also added Aidi Injection 50 mL / d intravenously (days 1 to 14). Results: The complete response rate was 75.00% in the observation group and 62.50% in the control group, with significant difference between the two groups (P <0.05). The total effective rate was 85.00% in the observation group and 75.00% in the control group (P <0.05). The 1-year survival rate was 65.00% in the observation group and 45.00% in the control group, and there was significant difference between the two groups (P <0.05). The 3-year survival rate was 37.50% in the observation group and 25.00% in the control group, (P <0.05). (25.7 ± 6.2) (23.3 ± 3.7) (23.7 ± 6.4) and (22.4 ± 4.6) points in the observation group after physical therapy, mental health, social relationship and environmental factors, respectively, while those in the control group were (15.7 ± 6.2) and (14.3 ± 3.7) (14.7 ± 6.4) (17.4 ± 4.6) points respectively. Both groups were significantly improved (P <0.05), which was better than the control group (P <0.05). Conclusion: Aidi injection combined with CAG regimen in the treatment of senile acute myeloid leukemia is effective, relatively safe and well tolerated.